Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Presynaptic adenosine A 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus

Presynaptic adenosine A 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP... We previously reported a presynaptic facilitatory action of A2A receptors on GABAergic synaptic transmission in the rat globus pallidus (GP). In the present study we identify the intracellular signalling mechanisms responsible for this facilitatory action of A2A receptors, using biochemical and patch‐clamp methods in rat GP slices. The adenosine A2A receptor selective agonist CGS21680 (1, 10 μM) and the adenylyl cyclase activator forskolin (1, 10 μM) both significantly increased cyclic AMP accumulation in GP slices. The CGS21680 (1 μM)‐mediated increase in cyclic AMP was inhibited by the A2A receptor selective antagonist KF17837 (10 μM). In an analysis of miniature inhibitory postsynaptic currents (mIPSCs), forskolin (10 μM) increased the mIPSC frequency without affecting their amplitude distribution, a result similar to that previously reported with CGS21680. The adenylyl cyclase inhibitor 9‐(tetrahydro‐2‐furanyl)‐9H‐purin‐6‐amine (SQ22,536, 300 μM) abolished the CGS21680‐induced enhancement in the frequency of mIPSCs. H‐89 (10 μM), a selective inhibitor for cyclic AMP‐dependent protein kinase (PKA), blocked the CGS21680‐induced enhancement of the mIPSC frequency. The calcium channel blocker CdCl2 (100 μM) did not prevent CGS21680 from increasing the frequency of mIPSCs. These results indicate that A2A receptor‐mediated potentiation of mIPSCs in the GP involves the sequential activation of the A2A receptor, adenylyl cyclase, and then PKA, and that this facilitatory modulation could occur independently of presynaptic Ca2+ influx. British Journal of Pharmacology (2002) 136, 296–302; doi:10.1038/sj.bjp.0704702 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Presynaptic adenosine A 2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus

Loading next page...
 
/lp/wiley/presynaptic-adenosine-a-2a-receptors-enhance-gabaergic-synaptic-b8iBf3mNYm

References (38)

Publisher
Wiley
Copyright
2002 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
DOI
10.1038/sj.bjp.0704702
pmid
12010779
Publisher site
See Article on Publisher Site

Abstract

We previously reported a presynaptic facilitatory action of A2A receptors on GABAergic synaptic transmission in the rat globus pallidus (GP). In the present study we identify the intracellular signalling mechanisms responsible for this facilitatory action of A2A receptors, using biochemical and patch‐clamp methods in rat GP slices. The adenosine A2A receptor selective agonist CGS21680 (1, 10 μM) and the adenylyl cyclase activator forskolin (1, 10 μM) both significantly increased cyclic AMP accumulation in GP slices. The CGS21680 (1 μM)‐mediated increase in cyclic AMP was inhibited by the A2A receptor selective antagonist KF17837 (10 μM). In an analysis of miniature inhibitory postsynaptic currents (mIPSCs), forskolin (10 μM) increased the mIPSC frequency without affecting their amplitude distribution, a result similar to that previously reported with CGS21680. The adenylyl cyclase inhibitor 9‐(tetrahydro‐2‐furanyl)‐9H‐purin‐6‐amine (SQ22,536, 300 μM) abolished the CGS21680‐induced enhancement in the frequency of mIPSCs. H‐89 (10 μM), a selective inhibitor for cyclic AMP‐dependent protein kinase (PKA), blocked the CGS21680‐induced enhancement of the mIPSC frequency. The calcium channel blocker CdCl2 (100 μM) did not prevent CGS21680 from increasing the frequency of mIPSCs. These results indicate that A2A receptor‐mediated potentiation of mIPSCs in the GP involves the sequential activation of the A2A receptor, adenylyl cyclase, and then PKA, and that this facilitatory modulation could occur independently of presynaptic Ca2+ influx. British Journal of Pharmacology (2002) 136, 296–302; doi:10.1038/sj.bjp.0704702

Journal

British Journal of PharmacologyWiley

Published: May 1, 2002

There are no references for this article.